Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.

Oncology - 1 Jan 2012

Peck Joshua, Wei Lai, Zalupski Mark, O'Neil Bert, Villalona Calero Miguel, Bekaii-Saab Tanios

Abstract excerpt

PURPOSE: Biliary cancers (BCs) respond poorly to chemotherapy. Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in cholangiocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in BC. METHODS: A Fleming phase II design with a single stage of 25 patients was used. The dose of lapatinib was 1,500 mg/day administered orally in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biliary Tract Neoplasms
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lapatinib

Share to Maximum Tolerated Dose

Share to Neoplasm Metastasis

Share to Quinazolines

Share to Receptor, ErbB-2

Share to Survival Rate

Source

Identifiers

PMID: 22433475
DOI: 10.1159/000336488

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.PMID 22433475Read ↗

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.Semantic proximity Read ↗

Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations.Semantic proximity Read ↗

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.Semantic proximity Read ↗

Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.Semantic proximity Read ↗

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.Semantic proximity Read ↗

Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer.Semantic proximity Read ↗

Anti‐tumour effect of lapatinib in canine transitional cell carcinoma cell linesSemantic proximity Read ↗

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.Semantic proximity Read ↗

A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer.Semantic proximity Read ↗

Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.